Radius publishes data on its research in osteoporosis in a variety of scientific or medical journals. Below are select articles relating to the development of abaloparatide.
Abaloparatide In Patients with Mild or Moderate Renal Impairment: Results from the ACTIVE Phase 3 Trial.
Curr Med Res Opin. 2019; August 16 [Epub ahead of print]. Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE.
Abaloparatide Improves Cortical Geometry and Trabecular Microarchitecture and Increases Vertebral and Femoral Neck Strength in a Rat Model of Male Osteoporosis.
BONE. 2019; 124:148-157. Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B.
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: a Network Meta-Analysis.
Osteoporosis International. 2019; 30(7):1465-1473. Reginster JY, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA.
Abaloparatide Effect on Forearm Bone Mineral Density and Wrist Fracture Risk in Postmenopausal Women with Osteoporosis.
Osteoporosis International. 2019; 30(6):1187-1194. Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F.
Challenges in Osteoporosis Awareness and Management: Results from a Survey of US Postmenopausal Women.
Journal of Drug Assessment. 2019; 8(1):25-31. Lewiecki EM, Leader D, Weiss R, Williams SA.
Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture.
Journal of Orthopaedic Research. 2019; 37(4):812-820. Lanske B, Chandler H, Pierce A, Brown J, Ominsky M, Kostenuik P, Hattersley G.
Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
Archives of Osteoporosis. 2019;14(1):15. McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA.
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Seminars in Arthritis and Rheumatism. 2019; Jan 10 [Epub ahead of print]. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY.
Bone Turnover Markers to Explain Changes in Lumbar Spine BMD with Abaloparatide and Teriparatide: Results from ACTIVE.
Osteoporos Int. 2019; 30(3):667-673. Eastell R, Mitlak B, Wang Y, Hu MY, Fitzpatrick LA, Black DM.
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
Bone. 2018;120:137-140. Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C.
Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
Bone. 2018;120:148-155. Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G.
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Ann Pharmacother. 2018;53(2):134-143. Le QA, Hay JW, Becker R, Wang Y.
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
Menopause. 2018;25:767-771. McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F.
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
Calcif Tissue Int. 2018;103:540-545. Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM.
ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
J Clin Endocrinol Metab. 2018;103:2949-2957. Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu M-y, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
Calcif Tissue Int. 2018;102:627-633. McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD.
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Osteoporos Int. 2018;29:685-697. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G.
Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Osteoporos Int. 2018;29:323-328. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.
The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.
J Bone Miner Res. 2017;32:1625-1631. McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA.
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Regul Toxicol Pharmacol. 2017;86:356-365. Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G.
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial.
Bone. 2017;97:314-319. Moreira C, Fitzpatrick LA, Wang Y, Recker RR.
Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial.
Mayo Clin Proc. 2017;92:200-210. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.
One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Bone. 2017;95:143-150. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.
One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption.
J Bone Miner Res. 2017;32:24-33. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G.
Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors.
J Bone Miner Res. 2017;32:17-23. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM.
Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats.
Calcif Tissue Int. 2016;99:489-499. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G.
Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.
JAMA. 2016;316:722-733. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.
Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling.
Endocrinology. 2016;157:141-149. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ.
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2015;100:697-706. Leder BZ, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.